Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
View ORCID ProfileVincent Auvigne, View ORCID ProfileCynthia Tamandjou, View ORCID ProfileJustine Schaeffer, View ORCID ProfileSophie Vaux, Isabelle Parent du Chatelet
doi: https://doi.org/10.1101/2023.03.17.23287411
Vincent Auvigne
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Cynthia Tamandjou
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Justine Schaeffer
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Sophie Vaux
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Isabelle Parent du Chatelet
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France

- Supplementary material[supplements/287411_file02.pdf]
Posted March 18, 2023.
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Subject Area
Subject Areas
- Addiction Medicine (280)
- Allergy and Immunology (580)
- Anesthesia (141)
- Cardiovascular Medicine (1965)
- Dermatology (187)
- Emergency Medicine (336)
- Epidemiology (11124)
- Gastroenterology (630)
- Genetic and Genomic Medicine (3202)
- Geriatric Medicine (310)
- Health Economics (567)
- Health Informatics (2051)
- Health Policy (864)
- Hematology (310)
- HIV/AIDS (686)
- Medical Education (319)
- Medical Ethics (92)
- Nephrology (339)
- Neurology (3004)
- Nursing (167)
- Nutrition (466)
- Oncology (1563)
- Ophthalmology (478)
- Orthopedics (186)
- Otolaryngology (266)
- Pain Medicine (203)
- Palliative Medicine (57)
- Pathology (403)
- Pediatrics (915)
- Primary Care Research (356)
- Public and Global Health (5616)
- Radiology and Imaging (1102)
- Respiratory Medicine (764)
- Rheumatology (342)
- Sports Medicine (290)
- Surgery (348)
- Toxicology (48)
- Transplantation (159)
- Urology (133)